A detailed history of Charles Schwab Investment Management Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 487,348 shares of ALNY stock, worth $119 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
487,348
Previous 470,592 3.56%
Holding current value
$119 Million
Previous $114 Million 17.23%
% of portfolio
0.03%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$233.81 - $287.01 $3.92 Million - $4.81 Million
16,756 Added 3.56%
487,348 $134 Million
Q2 2024

Aug 12, 2024

BUY
$143.31 - $247.0 $3.3 Million - $5.69 Million
23,032 Added 5.15%
470,592 $114 Million
Q1 2024

May 08, 2024

BUY
$146.51 - $198.2 $1.36 Million - $1.83 Million
9,256 Added 2.11%
447,560 $66.9 Million
Q4 2023

Feb 06, 2024

BUY
$151.41 - $196.57 $2.93 Million - $3.8 Million
19,324 Added 4.61%
438,304 $83.9 Million
Q3 2023

Nov 08, 2023

BUY
$170.77 - $211.65 $484,303 - $600,239
2,836 Added 0.68%
418,980 $74.2 Million
Q2 2023

Aug 09, 2023

BUY
$185.01 - $212.05 $1.99 Million - $2.29 Million
10,781 Added 2.66%
416,144 $79 Million
Q1 2023

May 11, 2023

BUY
$182.66 - $235.53 $874,393 - $1.13 Million
4,787 Added 1.2%
405,363 $81.2 Million
Q4 2022

Feb 13, 2023

BUY
$185.53 - $241.31 $4.03 Million - $5.24 Million
21,711 Added 5.73%
400,576 $95.2 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $355,770 - $595,776
2,568 Added 0.68%
378,865 $75.8 Million
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $442,423 - $621,971
3,674 Added 0.99%
376,297 $54.9 Million
Q1 2022

May 13, 2022

BUY
$127.18 - $173.91 $1.23 Million - $1.68 Million
9,662 Added 2.66%
372,623 $60.8 Million
Q4 2021

Feb 11, 2022

BUY
$159.56 - $209.29 $1.62 Million - $2.12 Million
10,146 Added 2.88%
362,961 $61.6 Million
Q3 2021

Nov 16, 2021

BUY
$169.75 - $207.73 $1.61 Million - $1.97 Million
9,484 Added 2.76%
352,815 $66.6 Million
Q2 2021

Aug 16, 2021

BUY
$128.63 - $176.89 $1.17 Million - $1.61 Million
9,118 Added 2.73%
343,331 $58.2 Million
Q1 2021

May 17, 2021

SELL
$126.83 - $175.69 $8.38 Million - $11.6 Million
-66,063 Reduced 16.5%
334,213 $47.2 Million
Q4 2020

Feb 16, 2021

SELL
$122.97 - $147.0 $37,259 - $44,541
-303 Reduced 0.08%
400,276 $52 Million
Q3 2020

Nov 13, 2020

SELL
$121.19 - $165.49 $27.8 Million - $37.9 Million
-229,065 Reduced 36.38%
400,579 $58.3 Million
Q2 2020

Aug 14, 2020

BUY
$104.21 - $156.44 $1.96 Million - $2.94 Million
18,825 Added 3.08%
629,644 $93.3 Million
Q1 2020

May 15, 2020

BUY
$93.12 - $133.99 $935,017 - $1.35 Million
10,041 Added 1.67%
610,819 $66.5 Million
Q4 2019

Feb 07, 2020

BUY
$74.51 - $124.23 $691,303 - $1.15 Million
9,278 Added 1.57%
600,778 $69.2 Million
Q3 2019

Nov 08, 2019

BUY
$70.9 - $87.82 $7.04 Million - $8.72 Million
99,325 Added 20.18%
591,500 $47.6 Million
Q2 2019

Aug 09, 2019

BUY
$65.86 - $92.79 $1.39 Million - $1.96 Million
21,151 Added 4.49%
492,175 $35.7 Million
Q1 2019

May 14, 2019

BUY
$72.76 - $93.45 $8.36 Million - $10.7 Million
114,879 Added 32.26%
471,024 $44 Million
Q4 2018

Feb 14, 2019

BUY
$62.67 - $88.33 $820,914 - $1.16 Million
13,099 Added 3.82%
356,145 $26 Million
Q3 2018

Nov 13, 2018

BUY
$87.52 - $122.67 $3.4 Million - $4.76 Million
38,813 Added 12.76%
343,046 $30 Million
Q2 2018

Aug 08, 2018

BUY
$88.31 - $107.8 $2.37 Million - $2.9 Million
26,881 Added 9.69%
304,233 $30 Million
Q1 2018

May 07, 2018

BUY
$115.92 - $148.54 $1.73 Million - $2.22 Million
14,936 Added 5.69%
277,352 $33 Million
Q4 2017

Jan 17, 2018

BUY
$114.49 - $139.98 $2.05 Million - $2.5 Million
17,866 Added 7.31%
262,416 $33.3 Million
Q3 2017

Nov 13, 2017

BUY
$72.53 - $118.27 $17.7 Million - $28.9 Million
244,550
244,550 $28.7 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.